Alopecia Totalis

15 registered clinical trials studyying Alopecia Totalis — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Evaluation of Microbiota Transplant Therapy in Patients With Alopecia Areata NCT06747611	University of Minnesota	Phase 2
Recruiting	Systemic Treatments for Alopecia Areata Registry NCT06283316	Erasmus Medical Center	—
Completed	Efficacy of Oral Tofacitinib in Moderate to Severe Alopecia Areata, Totalis and Universalis at Tertiary Care H NCT06278402	Jinnah Hospital	Phase 3
Completed	Study of EQ101 in Adult Subjects With Moderate to Severe Alopecia Areata NCT05589610	Equillium	Phase 2
Unknown	Clinical Application of Stem Cell Educator Therapy in Alopecia Areata NCT04011748	Throne Biotechnologies Inc.	Phase 2
Completed	The Epidemiology, Management and Comorbidities in Alopecia Areata in Czech Republic NCT05098600	Faculty Hospital Kralovske Vinohrady	—
Withdrawn	Phase 2 Trial of BNZ-1 in Patients With Moderate to Severe Alopecia Areata NCT03532958	Equillium	Phase 2
Withdrawn	Clinical Trial to Evaluate the Efficacy of Fecal Microbiota Transplantation in Patients With Alopecia Areata NCT04238091	Lindsey Bordone	Phase 2
Terminated	ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Tot NCT03759340	Aclaris Therapeutics, Inc.	Phase 2
Completed	Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due to Alopeci NCT03551821	Aclaris Therapeutics, Inc.	Phase 2
Completed	Topical Tofacitinib for the Treatment of Alopecia Areata and Its Variants NCT02812342	Yale University	Phase 2
Completed	Tofacitinib for the Treatment of Alopecia Areata and Its Variants NCT02312882	Stanford University	N/A
Withdrawn	Efalizumab in the Treatment of Alopecia, Phase II NCT00746980	Northwestern University	Phase 2
Completed	Safety and Efficacy of Oral Mega Pulse Methylprednisolone in Severe Therapy Resistant Alopecia Areata NCT01167946	King Saud University	Phase 4
Active Not Recruiting	Alopecia Areata Registry NCT00069589	M.D. Anderson Cancer Center	—